SGMT
Sagimet Biosciences Inc

2,014
Mkt Cap
$188.49M
Volume
330.00
52W High
$11.41
52W Low
$1.73
PE Ratio
-3.40
SGMT Fundamentals
Price
$6.08
Prev Close
$6.56
Open
$6.61
50D MA
$6.18
Beta
0.00
Avg. Volume
739,964.50
EPS (Annual)
-$1.45
P/B
1.66
Rev/Employee
$0.00
Loading...
Loading...
News
all
press releases
Sagimet Biosciences' (SGMT) "Buy" Rating Reaffirmed at HC Wainwright
HC Wainwright reiterated a "buy" rating and issued a $29.00 price objective on shares of Sagimet Biosciences in a research report on Tuesday...
MarketBeat·2d ago
News Placeholder
More News
News Placeholder
Sagimet Biosciences (NASDAQ:SGMT) Earns Buy Rating from Analysts at Guggenheim
Guggenheim started coverage on shares of Sagimet Biosciences in a report on Tuesday. They set a "buy" rating and a $27.00 target price on the stock...
MarketBeat·2d ago
News Placeholder
Ascletis Announces Positive Topline Results from Its Phase III Open-Label Study of Denifanstat (ASC40), a First-in-Class, Once-Daily Oral FASN Inhibitor for Acne
Ascletis Announces Positive Topline Results from Its Phase III Open-Label Study of Denifanstat (ASC40), a First-in-Class, Once-Daily Oral FASN Inhibitor for Acne Ascletis Announces Positive Topline...
PR Newswire·7d ago
News Placeholder
Sagimet Biosciences Inc. (NASDAQ:SGMT) Given Consensus Recommendation of "Moderate Buy" by Analysts
Shares of Sagimet Biosciences Inc. (NASDAQ:SGMT - Get Free Report) have been assigned a consensus rating of "Moderate Buy" from the eight ratings firms that are covering the company, MarketBeat...
MarketBeat·19d ago
News Placeholder
Sagimet Biosciences Inc. (NASDAQ:SGMT) Given Average Rating of "Moderate Buy" by Brokerages
Shares of Sagimet Biosciences Inc. (NASDAQ:SGMT - Get Free Report) have been given an average recommendation of "Moderate Buy" by the eight ratings firms that are currently covering the stock...
MarketBeat·1mo ago
News Placeholder
Sagimet Biosciences (NASDAQ:SGMT) Stock Price Up 5.4% - Still a Buy?
Sagimet Biosciences (NASDAQ:SGMT) Trading Up 5.4% - Time to Buy...
MarketBeat·2mo ago
News Placeholder
Ascletis Announces China National Medical Products Administration Acceptance of New Drug Application for Denifanstat (ASC40), a First-in-Class FASN Inhibitor for Acne Treatment
Ascletis Announces China National Medical Products Administration Acceptance of New Drug Application for Denifanstat (ASC40), a First-in-Class FASN Inhibitor for Acne Treatment Ascletis Announces...
PR Newswire·2mo ago
News Placeholder
Sagimet Biosciences Inc. (NASDAQ:SGMT) Receives Consensus Recommendation of "Moderate Buy" from Analysts
Sagimet Biosciences Inc. (NASDAQ:SGMT - Get Free Report) has been assigned an average recommendation of "Moderate Buy" from the nine brokerages that are covering the company, Marketbeat reports. One...
MarketBeat·2mo ago
News Placeholder
Sagimet Biosciences (NASDAQ:SGMT) Downgraded to Sell Rating by Wall Street Zen
Wall Street Zen downgraded shares of Sagimet Biosciences from a "hold" rating to a "sell" rating in a research note on Saturday...
MarketBeat·2mo ago
News Placeholder
Insider Selling: Sagimet Biosciences (NASDAQ:SGMT) Chairman Sells 37,688 Shares of Stock
Sagimet Biosciences Inc. (NASDAQ:SGMT - Get Free Report) Chairman George Kemble sold 37,688 shares of the company's stock in a transaction on Thursday, November 20th. The shares were sold at an...
MarketBeat·2mo ago
<
1
2
...
>

Latest SGMT News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.